Amylyx Pharma shares are trading higher despite reporting weak Q2 results. The market may be looking ahead to a pivotal Phase 3 LUCIDITY trial data readout, with strong cash reserves and clear regulatory strategy reducing risk and fueling optimism.

Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57

Benzinga Bulls and Bears: Ross, Moderna, Webull

Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.

8-K filing — Amylyx Pharmaceuticals, Inc. (AMLX)

Filed: 2026-08-20 AccNo: 0001193125-26-359418 Size: 411 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits

Reported Earlier, Amylyx Pharmaceuticals Prices Upsized $500M Public Offering Of 14,090,000 Common Shares At $35.50 Per Share